nach oben

Lung

Erschienen in:

07.09.2016

Methotrexate-Induced Epithelial–Mesenchymal Transition in the Alveolar Epithelial Cell Line A549

verfasst von: Masashi Kawami, Rika Harabayashi, Mioka Miyamoto, Risako Harada, Ryoko Yumoto, Mikihisa Takano

Erschienen in: Lung | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Methotrexate (MTX) therapy of certain cancers and rheumatoid arthritis often induces serious interstitial lung complications including pulmonary fibrosis. In this study, we investigated the epithelial–mesenchymal transition (EMT) induced by MTX and by transforming growth factor (TGF)-β1 in the human alveolar epithelial cell line A549 in order to develop new strategies for the prevention of EMT.

Methods

First, we examined the effect of TGF-β1 and MTX on cell morphology and the expression of EMT-related mRNAs in A549 cells. Then, the effects of SB431542 (SB), a potent inhibitor of TGF-β receptor kinase, and a neutralizing antibody for TGF-β1 on the phenotypic changes of A549 cells induced by TGF-β1 and MTX were examined.

Results

After incubation with TGF-β1 and MTX, the mRNA expression of epithelial markers such as cytokeratin 19 was reduced, while that of mesenchymal markers such as α-smooth muscle actin was increased. SB suppressed the development of morphological changes and partially rescued alterations in mRNA expression of EMT markers induced by MTX. In addition, the enhancement of SMAD2 phosphorylation by MTX was also prevented by SB. On the other hand, EMT-related changes induced by MTX were not affected by a neutralizing antibody for TGF-β1.

Conclusion

We have demonstrated that phenotypic changes of A549 cells induced by MTX are partly mediated by a TGF-β1-related intracellular signaling pathway, although TGF-β1 itself is not directly involved in this process.

Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404–417CrossRefPubMed

Cronstein BN (2006) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163–172CrossRef

Niehues T, Lankisch P (2006) Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr Drugs 8:347–356CrossRefPubMed

Calvo I, Anton J, Lopez Robledillo JC et al. (2015) Recommendations for the use of methotrexate in patients with juvenile idiopathic arthritis. An Pediatr (Barc)

Kim KK, Kugler MC, Wolters PJ et al (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 103:13180–13185CrossRefPubMedPubMedCentral

Thiery JP, Acloque H, Huang RY et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890CrossRefPubMed

Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196CrossRefPubMedPubMedCentral

Moeller A, Ask K, Warburton D et al (2008) The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40:362–382CrossRefPubMed

Wynn TA (2011) Integrating mechanisms of pulmonary fibrosis. J Exp Med 208:1339–1350CrossRefPubMedPubMedCentral

10.

Gonzalez DM, Medici D (2014) Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 7:re8CrossRefPubMedPubMedCentral

11.

Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67:753–791CrossRefPubMed

12.

Mei Q, Saiz L (2014) Literature-based automated reconstruction, expansion, and refinement of the TGF-beta superfamily ligand-receptor network. J Membr Biol 247:381–386CrossRefPubMed

13.

Massague J (2008) TGFbeta in Cancer. Cell 134:215–230CrossRefPubMedPubMedCentral

14.

Attisano L, Lee-Hoeflich ST (2001) The Smads. Genome Biol 2: Reviews 3010

15.

Willis BC, Borok Z (2007) TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 293:L525–L534CrossRefPubMed

16.

Chen LJ, Ye H, Zhang Q et al (2015) Bleomycin induced epithelial-mesenchymal transition (EMT) in pleural mesothelial cells. Toxicol Appl Pharmacol 283:75–82CrossRefPubMed

17.

Ohbayashi M, Kubota S, Kawase A et al (2014) Involvement of epithelial-mesenchymal transition in methotrexate-induced pulmonary fibrosis. J Toxicol Sci 39:319–330CrossRefPubMed

18.

Takano M, Yamamoto C, Yamaguchi K et al (2015) Analysis of TGF-beta1- and drug-induced epithelial-mesenchymal transition in cultured alveolar epithelial cell line RLE/Abca3. Drug Metab Pharmacokinet 30:111–118CrossRefPubMed

19.

Kasai H, Allen JT, Mason RM et al (2005) TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 6:56CrossRefPubMedPubMedCentral

20.

Kim JH, Jang YS, Eom KS et al (2007) Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells. J Korean Med Sci 22:898–904CrossRefPubMedPubMedCentral

21.

Kawami M, Miyamoto M, Yumoto R et al (2015) Methotrexate influx via folate transporters into alveolar epithelial cell line A549. Drug Metab Pharmacokinet 30:276–281CrossRefPubMed

22.

Cronstein BN (1996) Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 39:1951–1960CrossRefPubMed

23.

Lynch JP 3rd, McCune WJ (1997) Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 155:395–420CrossRefPubMed

24.

van Ede AE, Laan RF, Blom HJ et al (1998) Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 27:277–292CrossRefPubMed

25.

Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784CrossRefPubMedPubMedCentral

26.

Iwano M, Plieth D, Danoff TM et al (2002) Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110:341–350CrossRefPubMedPubMedCentral

27.

Bonniaud P, Margetts PJ, Kolb M et al (2005) Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 171:889–898CrossRefPubMed

28.

Higashiyama H, Yoshimoto D, Kaise T et al (2007) Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol 83:39–46CrossRefPubMed

29.

Inman GJ, Nicolas FJ, Callahan JF et al (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65–74CrossRefPubMed

30.

Koyama S, Sato E, Takamizawa A et al (2003) Methotrexate stimulates lung epithelial cells to release inflammatory cell chemotactic activities. Exp Lung Res 29:91–111CrossRefPubMed

31.

Kim YJ, Song M, Ryu JC (2009) Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicol 256:183–190CrossRef

32.

Wu D, Cheng J, Sun G et al (2016) p70S6 K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma. Oncotarget. doi:10.18632/oncotarget.9282

Titel: Methotrexate-Induced Epithelial–Mesenchymal Transition in the Alveolar Epithelial Cell Line A549
verfasst von: Masashi Kawami
Rika Harabayashi
Mioka Miyamoto
Risako Harada
Ryoko Yumoto
Mikihisa Takano
Publikationsdatum: 07.09.2016
Verlag: Springer US
Erschienen in: Lung / Ausgabe 6/2016
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-016-9935-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions

The Association Between Bone Mineral Density and Airflow Limitation in a Cohort of Fit Elderly Women

Lung Clearance Index (LCI) in Patients with Bronchiolitis Obliterans: A Preliminary Report and Comparison to Cystic Fibrosis Patients

Selection of Patients in Ongoing Clinical Trials on Lung Cancer

Intermittent Hypoxia Contributes to the Lung Damage by Increased Oxidative Stress, Inflammation, and Disbalance in Protease/Antiprotease System